COVID-19 inflammation and implications in drug delivery-Reference-Cited by-同舟云学术

COVID-19 inflammation and implications in drug delivery

Published:2022-06 Issue: Volume:346 Page:260-274
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Zoulikha Makhloufi,Huang Feifei,Wu Zhenfeng,He Wei

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference187 articles.

1. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment;Subramanian;J. Biomol. Struct. Dyn.,2021

2. Structure genomics of SARS-CoV-2 and its Omicron variant : drug design templates for COVID-19;Wu;Acta Pharmacol. Sin.,2022

3. A scoping review of the pathophysiology of COVID-19;Marik;Int. J. Immunopathol. Pharmacol.,2021

4. COVID-19 pathophysiology : A review;Yuki;Clin. Immunol.,2020

5. Immunomodulation and regenerative capacity of MSCs for long-COVID;Loke;Int. J. Mol. Sci.,2021

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Mild Cases to Critical Cases of COVID-19: The Role of Genes in Inflammasome and Mitochondrial Dynamics;Iranian Journal of Allergy, Asthma and Immunology;2024-08-10

2. Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments;International Journal of Pharmaceutics;2024-07

3. The interaction between particles and vascular endothelium in blood flow;Advanced Drug Delivery Reviews;2024-04

4. Harnessing self-assembled nanoplatform of Dexamethasone and α-linolenic acid for high-efficiency inhibition of pulmonary cytokine storm and fibrosis in mice;Nano Today;2024-04

5. Multifunctional nanoparticle-mediated combining therapy for human diseases;Signal Transduction and Targeted Therapy;2024-01-01